Ulcerative colitis: bacteria findings raise hopes for new treatment
Sufferers found to have low levels of gut microbes that convert bile acids into other substancesHopes of developing a new treatment for ulcerative colitis have been raised by research suggesting the condition may be linked to low levels of certain bacteria in the gut.Ulcerative colitis is a long-term condition in whichthe colon becomes inflamed. Accordingto the NHS, it is thought to be an autoimmune disease and affects one in every 420 people in the UK. Sufferers need to empty their bowels frequently, develop ulcers in their colon and have recurring bouts of diarrhoea with blood and pus in the faeces.Continue reading... (S...
Source: Guardian Unlimited Science - February 25, 2020 Category: Science Authors: Nicola Davis Tags: Digestive disorders Science Health & wellbeing Life and style Society Source Type: news
FDA accepts Roche ’s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer
Basel, 25 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for the fixed-dose combination (FDC) of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subc utaneous (SC) injection in combination with intravenous (IV) chemotherapy, for the treatment of eligible patients with HER2-positive breast cancer. The BLA for the FDC is based on results from the phase III FeDeriCa study, which demonstrated non-inferior levels of Perjeta in the blood (pharmacokinet ics)...
Source: Roche Investor Update - February 25, 2020 Category: Pharmaceuticals Source Type: news
FDA accepts Roche ’s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer
Basel, 25 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for the fixed-dose combination (FDC) of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subc utaneous (SC) injection in combination with intravenous (IV) chemotherapy, for the treatment of eligible patients with HER2-positive breast cancer. The BLA for the FDC is based on results from the phase III FeDeriCa study, which demonstrated non-inferior levels of Perjeta in the blood (pharmacokinet ics)...
Source: Roche Media News - February 25, 2020 Category: Pharmaceuticals Source Type: news
Roche ’s risdiplam showed significant improvement in motor function in people aged 2-25 with type 2 or 3 spinal muscular atrophy
Basel, 06 February 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented 1-year data from the pivotal Part 2 of SUNFISH, a global placebo-controlled study evaluating risdiplam in people aged 2-25 years with Type 2 or 3 spinal muscular atrophy (SMA). The study showed that change from baseline in the primary endpoint of the Motor Function Measure scale (MFM-32)1 was significantly greater in people treated with risdiplam, compared to placebo (1.55 point mean difference; p=0.0156). The Revised Upper Limb Module (RULM),2 a key secondary endpoint, also showed an improvement (1.59 point difference; p=0.0028). Safety for risdi...
Source: Roche Media News - February 6, 2020 Category: Pharmaceuticals Source Type: news
Roche ’s risdiplam showed significant improvement in motor function in people aged 2-25 with type 2 or 3 spinal muscular atrophy
Basel, 6 February 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented 1-year data from the pivotal Part 2 of SUNFISH, a global placebo-controlled study evaluating risdiplam in people aged 2-25 years with Type 2 or 3 spinal muscular atrophy (SMA). The study showed that change from baseline in the primary endpoint of the Motor Function Measure scale (MFM-32)[1]was significantly greater in people treated with risdiplam, compared to placebo (1.55 point mean difference; p=0.0156). The Revised Upper Limb Module (RULM),[2] a key secondary endpoint, also showed an improvement (1.59 point difference; p=0.0028). Safety for ris...
Source: Roche Investor Update - February 6, 2020 Category: Pharmaceuticals Source Type: news
Roche announces CHMP recommendation for EU approval of Venclyxto plus Gazyvaro for people with untreated chronic lymphocytic leukaemia
Basel, 31 January 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Venclyxto® (venetoclax) in combination with Gazyvaro® (obinutuzumab) for the treatment of adults with previously untreated chronic lymphocytic leukaemia (CLL).“Despite advances in treating chronic lymphocytic leukaemia, many patients cannot tolerate the side effects of chemotherapy-containing regimens,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We’r...
Source: Roche Investor Update - January 31, 2020 Category: Pharmaceuticals Source Type: news
Leprosy Re-emerges as a Global Health Challenge
Sattamma, a daily labourer in the Rangareddy district of southern India’s Telangana state, says that even though she no longer has Hansen’s Disease, she remains discriminated against because of it. Credit: Stella Paul/IPSBy Stella PaulHYDERABAD, India , Jan 23 2020 (IPS) Fifteen years ago, Sattamma – a daily labourer in the Rangareddy district of southern India’s Telangana state – was abandoned by her husband after she was diagnosed with Hansen’s Disease.
Last October, while her neighbours were celebrating Diwali, Sattamma was homeless again as her landlord threw her out of the house after he discovered her pas...
Source: IPS Inter Press Service - Health - January 23, 2020 Category: International Medicine & Public Health Authors: Stella Paul Tags: Asia-Pacific Development & Aid Editors' Choice Featured Global Headlines Health Human Rights Latin America & the Caribbean Poverty & SDGs TerraViva United Nations Brazil Hansen's disease India Indonesia leprosy Source Type: news
La Niña climate cycle sparks 30% jump in cases of life-threatening diarrhoea in Africa'
Columbia University scientists studying La Niña's link to the killer illness found rates soared by a third in a region of Botswana worst-hit by flooding sparked by the climate anomaly. (Source: the Mail online | Health)
Source: the Mail online | Health - December 31, 2019 Category: Consumer Health News Source Type: news
Bacteria can 'outsmart' programmed cell death
(University of Cologne) To be able to multiply, bacteria that cause diarrhoea block mediators of programmed cell death, a new study in 'Nature Microbiology' shows. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - December 24, 2019 Category: Infectious Diseases Source Type: news
Tanzania: Viral Infections Leading Cause of Sickness
[Citizen] It is his second day since he started experiencing fever and vomiting then followed up by diarrhoea. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - December 10, 2019 Category: African Health Source Type: news
Schools and hospitals forced to shut after hundreds of pupils and patients stuck down by norovirus
Howden School in Goole and Parkside School in Bradford (pictured) have had to close this week because of outbreaks of an illness believed to be norovirus, which causes diarrhoea and vomiting. (Source: the Mail online | Health)
Source: the Mail online | Health - November 27, 2019 Category: Consumer Health News Source Type: news
Clinical effects from household insecticide: pyrethroid or organophosphate toxicity? - Basrai Z, Koh C, Celedon M, Warren J.
A 54-year-old man with a history of schizophrenia presented to the emergency room for weakness with associated lacrimosis, drooling, nausea, emesis, diarrhoea, diplopia and burning sensation on his skin that began 6 hours after spraying five cans of Raid... (Source: SafetyLit)
Source: SafetyLit - November 25, 2019 Category: International Medicine & Public Health Tags: Home and Consumer Product Safety Source Type: news
Yellow fever – Bolivarian Republic of Venezuela
On 13 November 2019, the Venezuela International Health Regulations (IHR) National Focal Point (NFP) and the Venezuela PAHO/WHO Country Office shared information about a confirmed case of yellow fever in Bolivar State. The case-patient is a 46-year-old male resident of the municipality of Gran Sabana, Bolivar State. He was in the locality of Uriman municipality of Gran Sabana within the 19 days prior to the onset of symptoms. Symptom onset was on 14 September 2019, and included fever, chills, nausea, vomiting, epistaxis, petechiae, and diarrhoea. On 26 September 2019, he visited a public hospital in the municipality of Her...
Source: WHO Disease Outbreaks - November 21, 2019 Category: Infectious Diseases Tags: news Source Type: news
“ Transformational Benefits ” of Ending Outdoor Defecation
A Dalit woman stands outside a dry toilet located in an upper caste villager’s home in Mainpuri, in the northern Indian state of Uttar Pradesh. Credit: Shai Venkatraman/IPSBy External SourceUNITED NATIONS, Nov 18 2019 (IPS) Ending the practice of defecating in the open, rather than in a toilet, will have “transformational benefits” for some of the world’s most vulnerable people, says the UN’s partner sanitation body, the WSSCC (Water Supply and Sanitation Collaborative Council).
Ahead of World Toilet Day, which is marked annually on 19 November, WSSCC’s acting Executive Director, Sue Coates, has been speaking ...
Source: IPS Inter Press Service - Health - November 18, 2019 Category: International Medicine & Public Health Authors: External Source Tags: Development & Aid Global Headlines Health Water & Sanitation Source Type: news
Climate crisis will affect lifelong health of young, warn doctors
Lancet Countdown tracks impacts of global heating covering disease, wildfires and malnutritionThe climate crisis will determine the lifelong health of today ’s children, doctors have warned, noting that global heating was already causing harm.Children are especially vulnerable and the global team of researchers say rising temperatures mean the bacteria causing deadly diarrhoea will thrive while poorer crop yields could lead to more malnutrition.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - November 13, 2019 Category: Science Authors: Damian Carrington Environment editor Tags: Climate change Global health Infectious diseases Malnutrition Wildfires Natural disasters and extreme weather Children Global development Environment World news UK news Science Agriculture Source Type: news
